EN
FR
Export
export
Export
PDF
Excel (XLSX)
Word (DOCX)
You can select particular sections to be included in the output file.
Select all
Select classic EML layout
Indication
ICD-11
ATC codes
List type
Formulations
Therapeutic alternatives
Footnote
INN
Medicine type
Antibiotic groups
Sex
Age
Age restriction
Weight restriction
Patent information
Expert Committee decision justification
Cancel
Download
EN
FR
Model List of Essential Medicines
clear
Found 25 recommendations for 18 medicines and 8 therapeutic equivalents
Removed medicines and rejected applications are not shown.
Show them
.
8.2.2. Targeted therapies
Afatinib
General information
Section
Targeted therapies
Indications
Therapeutic equivalent to
erlotinib
for
Other specified malignant neoplasms of bronchus or lung
All-trans retinoic acid
General information
Section
Targeted therapies
Oral > Solid: 10 mg capsule
Indications
Acute myeloid leukaemia with recurrent genetic abnormalities
Bortezomib
General information
Section
Targeted therapies
Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications
Plasma cell myeloma
Dasatinib
General information
Section
Targeted therapies
Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
Indications
Chronic myeloid leukaemia, not elsewhere classified
Erlotinib
General information
Section
Targeted therapies
Oral > Solid: 100 mg; 150 mg
Indications
Other specified malignant neoplasms of bronchus or lung
Everolimus
General information
Section
Targeted therapies
Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
Indications
Other specified gliomas of brain
Gefitinib
General information
Section
Targeted therapies
Indications
Therapeutic equivalent to
erlotinib
for
Other specified malignant neoplasms of bronchus or lung
Ibrutinib
General information
Section
Targeted therapies
Oral > Solid: 140 mg
Indications
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Imatinib
General information
Section
Targeted therapies
Oral > Solid: 100 mg; 400 mg
Indications
B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1
Gastrointestinal stromal tumour of unspecified gastrointestinal sites
Chronic myeloid leukaemia, not elsewhere classified
Nilotinib
General information
Section
Targeted therapies
Oral > Solid > capsule: 150 mg; 200 mg
Indications
Chronic myeloid leukaemia, not elsewhere classified
Rituximab
General information
Section
Targeted therapies
Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
Indications
Follicular lymphoma
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Diffuse large B-cell lymphomas
Burkitt lymphoma including Burkitt leukaemia
Trastuzumab
General information
Section
Targeted therapies
Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
Indications
Carcinoma of breast, specialised type